Shares fell 3.9% as investors reacted negatively to persistent weakness and declines in the interventional technologies segment, overshadowing solid growth elsewhere and a cautious stance on near-term growth drivers.

• Total revenue was $346 million in Q4, up 5% reported and 9% organic ex-CSL; full fiscal year revenue totaled $1.3 billion.
• Interventional technologies revenue fell 10% in Q4 and 9% for the year, with vascular closure down 8%, driven by share losses and ongoing procedural headwinds.
• Blood management technologies posted strong growth, with blood management up 21% in the quarter and 14% for the year, led by TEG 6s adoption and European expansion.
• Plasma franchise grew 3% reported and 13% organic ex-CSL in Q4, supported by strong U.S. and European share gains and new product launches like Persona PLUS.
• Fiscal 2027 guidance expects 4–7% reported revenue growth, excluding contribution from PerQseal Elite still under FDA review, highlighting cautious near-term expectations.